Abstract
Anaplastic lymphoma kinase (ALK) rearrangement is most commonly observed in lung adenocarcinoma in a subset of lung cancer. Large cell neuroendocrine carcinoma (LCNEC) harboring an ALK rearrangement is very rare. Based on the findings from a transbronchial lung biopsy, a 75-year-old non-smoking woman was diagnosed with LCNEC with multiple liver and bone metastases. After seven cycles of cytotoxic chemotherapy, her genotype testing demonstrated ALK rearrangement. Subsequently, she was administered alectinib and exhibited a partial response.
Keywords:
ALK rearrangement and alectinib; LCNEC; pulmonary neuroendocrine carcinoma.
MeSH terms
-
Aged
-
Anaplastic Lymphoma Kinase
-
Bone Neoplasms / secondary
-
Carbazoles / therapeutic use*
-
Carcinoma, Large Cell / drug therapy
-
Carcinoma, Large Cell / genetics*
-
Carcinoma, Large Cell / pathology
-
Carcinoma, Neuroendocrine / drug therapy
-
Carcinoma, Neuroendocrine / genetics*
-
Carcinoma, Neuroendocrine / pathology
-
Female
-
Gene Rearrangement*
-
Humans
-
Liver Neoplasms / secondary
-
Lung Neoplasms / drug therapy
-
Lung Neoplasms / genetics*
-
Lung Neoplasms / pathology
-
Piperidines / therapeutic use*
-
Protein Kinase Inhibitors / therapeutic use*
-
Receptor Protein-Tyrosine Kinases / genetics*
Substances
-
Carbazoles
-
Piperidines
-
Protein Kinase Inhibitors
-
ALK protein, human
-
Anaplastic Lymphoma Kinase
-
Receptor Protein-Tyrosine Kinases
-
alectinib